Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies
Zhou et al., bioRxiv, doi:10.1101/2022.02.15.480166 (Preprint) (In Vitro)
Zhou et al., SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies, bioRxiv, doi:10.1101/2022.02.15.480166 (Preprint) (In Vitro)
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In Vitro study showing that omicron BA.2 evades all monoclonal antibodies tested, including sotrovimab and tixagevimab/cilgavimab which retained activity for omicron BA.1.
4 In Vitro studies support the efficacy of sotrovimab [Liu, Sheward, VanBlargan, Zhou].
Zhou et al., 16 Feb 2022, preprint, 4 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperSotrovimabAll
Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2022.02.15.480166; this version posted February 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies Hao Zhou1,*, Takuya Tada1,*, Belinda M. Dcosta1,* and Nathaniel R. Landau1,# Affiliation: 1 Department of Microbiology, NYU Grossman School of Medicine, New York, NY, USA. *These authors contributed equally. #Corresponding author: Nathaniel R. Landau, Ph.D. NYU Grossman School of Medicine 430 East 29th Street, Alexandria West Building, Rm 509, New York, NY 10016 Email: nathaniel.landau@med.nyu.edu Phone: (212) 263-9197 1 bioRxiv preprint doi: https://doi.org/10.1101/2022.02.15.480166; this version posted February 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Keywords: SARS-CoV-2 variants, Omicron BA.2, monoclonal antibodies, spike protein, Sotrovimab, Evusheld. 2 bioRxiv preprint doi: https://doi.org/10.1101/2022.02.15.480166; this version posted February 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly successful in decreasing disease severity; however, the recent emergence of the heavily mutated Omicron variant has posed a challenge to this treatment strategy. The Omicron variant BA.1 has been found to evade neutralization by the Regeneron and Eli Lilly therapeutic monoclonal antibodies, while Sotrovimab and the Evusheld monoclonal antibody cocktail retain significant neutralizing activity. A newly emerged variant, Omicron BA.2, containing the BA.1 mutations plus an additional 6 mutations and 3 deletions, 3 of which lie in the receptor binding domain, has been found to be spreading with increased transmissibility. We report here, using a spike protein-pseudotyped lentivirus assay, that Omicron BA.2 is not neutralized with detectable titer by any of the therapeutic monoclonal antibodies, including Sotrovimab and the Evusheld monoclonal antibodies. The results demonstrate the difficulty of identifying broadly neutralizing monoclonal antibodies against SARS-CoV-2 and the importance of the T cell response from which immunoevasion is more difficult. 3 bioRxiv preprint doi: https://doi.org/10.1101/2022.02.15.480166; this version posted February 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Main text The BA.2 variant of the highly mutated Omicron SARS-CoV-2 variant identified in late 2021 in patients in countries including Denmark, South Africa and India (1) and since then, in more countries including the United States. BA.2 has been found to be 1.5-fold more transmissible than the already highly transmissible BA.1 variant and is thus expected to continue to increase in prevalence (2). The BA.2 spike protein has all of the mutations of BA.1 plus an additional 6 mutations and 3 deletions, three of which lie in the receptor binding domain (3) (Supplemental Figure 1A). Of the monoclonal antibodies authorized by the Food and..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit